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OBJECTIVE
Severe hypoglycemic events (SHEs) in type 2 diabetes are associated with subse-
quent cardiovascular (CV) event risk. We examined whether CV events were associ-
ated with subsequent SHE risk.
RESEARCH DESIGN AND METHODS
Time-dependent associations between SHEs and a composite CV end point (fatal/
nonfatal myocardial infarction or stroke, hospitalization for unstable angina, hospi-
talization for heart failure [hHF]) were examined post hoc in 14,671 TECOS (Trial
Evaluating Cardiovascular Outcomes With Sitagliptin) participants with type 2 di-
abetes and CV disease followed for a median of 3.0 years.
RESULTS
SHEs were uncommon and unassociated with sitagliptin therapy (N = 160 [2.2%],
0.78/100 patient-years vs.N = 143 [1.9%], 0.70/100 patient-years for placebo; hazard
ratio [HR] 1.12 [95%CI 0.89, 1.40],P = 0.33). Patientswith (versuswithout) SHEswere
older with longer diabetes duration, lower body weight, and lower estimated glo-
merularfiltration rate; weremore frequentlywomen, nonwhite, and insulin treated;
and more often had microalbuminuria or macroalbuminuria. Analyses adjusted for
clinical factors showed SHEs were associated with increased risk of the primary
composite CV end point (1.55 [1.06, 2.28], P = 0.025), all-cause death (1.83 [1.22,
2.75], P = 0.004), and CV death (1.72 [1.02, 2.87], P = 0.040). Conversely, nonfatal
myocardial infarction (3.02 [1.83, 4.96], P < 0.001), nonfatal stroke (2.77 [1.36, 5.63],
P = 0.005), and hHF (3.68 [2.13, 6.36], P < 0.001) were associated with increased risk
of SHEs. Fully adjustedmodels showedno association between SHEs and subsequent
CV or hHF events, but the association between CV events and subsequent SHEs
remained robust.
CONCLUSIONS
These findings, showing greater risk of SHEs after CV events and greater risk of CV
events after SHEs, suggest a common at-risk type 2 diabetes frail patient phenotype.
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Post hoc analyses of several large-scale,
long-term randomized cardiovascular
(CV) outcome trials evaluating glucose-
lowering drugs or strategies have identi-
fiedanassociation betweenhypoglycemia
and a subsequent increased risk of all-
cause mortality or CV mortality in peo-
ple with type 2 diabetes, as shown in
Supplementary Table 1 (1–5). This is par-
ticularly the case for patients experienc-
ing severe hypoglycemic events (SHEs),
with typically close to twice the risk of
CV death in those who have experienced
an SHE compared with those who have
not. As a result, many diabetes manage-
ment guidelines have been modified to
advocate less aggressive glycemic targets
to reduce the incidence of SHEs in the
belief that this will minimize mortality
risk (6,7), although less strict glycemic tar-
gets have not been shown to reduce the
risk of SHEs (8). However, it remains un-
clear whether SHEs have a causal role in
increasing CVmortality rates andwhether
more cautious glycemic targets, which
may increase the risk of microvascular dis-
ease in the longer term (9), arewarranted.
We conducted post hoc analyses of the
Trial Evaluating Cardiovascular Outcomes
With Sitagliptin (TECOS) (10) to better
elucidate the interrelationship between
SHEs and CV events. In TECOS, a wide
range of CV outcomes were collected as-
siduously and adjudicated, along with
prospective recordingof SHEsasanadverse
outcome of special interest in 14,671 par-
ticipants with type 2 diabetes and CV dis-
ease followed for a median of 3.0 years.
RESEARCH DESIGN AND METHODS
Study Design and Participants
TECOS was a multinational, double-blind,
placebo-controlled, randomized, event-
driven trial designed to assess the CV
safety of sitagliptin versus placebo when
added to usual care in patients with
type 2 diabetes and established CV dis-
ease, as reported previously (10). It was
designed and run jointly by the Duke Clin-
ical Research Institute (DCRI) and the Uni-
versity of Oxford Diabetes Trials Unit, in an
academically independent collaboration
with the sponsor, Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc.,
Kenilworth, NJ. The database was held at
and verified independently by the DCRI.
The protocol was approved by the ethics
committees associated with all TECOS
sites, andall participants providedwritten
informed consent for trial participation.
Eligible patients had type 2 diabetes
and preexisting coronary, cerebrovascu-
lar, or peripheral atherosclerotic vascular
disease,were$50 years of age, and had a
baseline glycated hemoglobin (HbA1c) of
48–64 mmol/mol (6.5–8.0%) on stable
antihyperglycemicmedication, i.e., mono-
therapy or dual-combination therapy with
metformin, pioglitazone, or sulfonylurea,
or insulin with or without metformin. Trial
exclusions included use of a dipeptidyl pep-
tidase 4 inhibitor, glucagon-like peptide
1 receptor agonist, or rosiglitazone during
the preceding 3 months; $2 SHEs in the
previous 12 months; or estimated glomeru-
lar filtration rate (eGFR) ,30 mL/min per
1.73m2 at baseline. Patientswith previous
heart failure were not excluded.
Randomization and Study Medication
Participants were assigned randomly 1:1
to treatment with sitagliptin 100mg daily
(50 mg daily if baseline eGFR was $30
and ,50 mL/min/1.73 m2) or matching
placebo, with predefined dose adjust-
ments throughout the trial based on eGFR
levels. HbA1c was measured locally at en-
rollment, at 4 and 8 months, and then
annually. Open-label addition and/or ti-
tration of antihyperglycemic medication
(other than adipeptidyl peptidase4 inhib-
itor or glucagon-like peptide 1 receptor
agonist) was encouraged throughout the
trial, targeting HbA1c levels in accord with
regional standards of care and individual-
ized treatment goals.
SHEs
At screening/enrollment, 4- and 8-month
visits, and then annual visits, the symp-
toms and appropriate management of
hypoglycemia were reviewed proactively
with participants. All SHEs were recorded
systematically as prespecifiedevents of clin-
ical interest. Theyweredefinedperprotocol
as episodes in which a participant was suf-
ficiently disoriented or incapacitated as to
require help from either another individual
or from medical personnel, i.e., third-party
assistance, irrespective of whether this as-
sistance was actually provided. It did not
suffice, for example, if a family member
or other bystander brought the participant
a snack or drink to help raise his or her
blood glucose if it was not clear that the
patient could not have done this unaided.
Patients who had$2 SHEs between study
visits, despite adjustment of open-label
glucose-lowering agents, were required
to discontinue study medication.
Clinical Outcomes
TheTECOSprimary 4-point compositema-
jor adverse cardiovascular event (MACE)
was defined as the first confirmed event
of CV death, nonfatal myocardial infarc-
tion (MI), nonfatal stroke, or hospitaliza-
tion for unstable angina. Other TECOS
secondary outcomes included 3-point
MACE (CV death, nonfatal MI, or nonfatal
stroke), fatal/nonfatal MI, fatal/nonfatal
stroke, all-cause death, and hospitalization
for heart failure (hHF). All of these events
were adjudicated by an independent clini-
cal events classification committee, whose
members were unaware of study group
assignments. Additional prespecified ex-
ploratory outcomes included changes in
HbA1c and eGFR levels, initiation of addi-
tional glucose-loweringagentsor long-term
insulin therapy, and frequency of SHEs.
Statistical Analysis
Categorical variables are presented as
number and percentage, and continuous
variables are presented as median (inter-
quartile range). Time to first SHE is shown
with Kaplan-Meier plots, with study treat-
ment differences tested using Cox propor-
tional hazards regressionmodels stratified
by region. Treatment effects for sitagliptin
versus placebo are presented as hazard
ratios (HRs) and 95% CIs, with numbers
of events and events per 100 patient-years
of follow-up reported.
To investigate the association between
SHEs and subsequent CV ormortality out-
comes, Cox regressionmodels were fitted
with SHE as a time-dependent variable.
Modelswere repeatedwith partial adjust-
ment for selected clinical factors (age, sex,
race, smoking, and weight) and with full
adjustment. Covariates were chosen for
inclusion in the full adjustment model if
they were selected for the 3-point MACE
endpoint usingCoxmodelswithbackward
elimination, with a = 0.05 required for re-
tention. Because common risk factors of-
ten underlie multiple conditions, it is
reasonable to assume that modeling a
composite end point would select the
major confounders. Significant variables
were age, sex, race, ethnicity, HbA1c,
New York Heart Association class, smok-
ing, MI, chronic obstructive pulmonary
disease, coronary artery disease, stroke,
$50% stenosis of carotid artery, atrial fi-
brillation or flutter, insulin therapy, am-
putation, diabetic neuropathy, foot ulcer,
blood pressure, heart rate, height, BMI, and
eGFR.Randomized treatment anddiabetes
duration were included due to clinical rel-
evance, and region was included as a
strata variable for consistency with the
TECOS primary results article (10). For
the continuous variables, the linearity as-
sumption of Cox proportional hazards re-
gression models was checked for all end
points. Where piecewise splines for con-
tinuous variables were necessary, a cut
point was selected that would work rea-
sonably well for all end points. The propor-
tional hazards assumption was checked for
the full adjustment model, and no major
violations were identified. Multiple impu-
tationby the fully conditional specification
method with regression was used, via SAS
PROC MI (SAS Institute, Inc., Cary, NC), to
create 25 imputed data sets of baseline
characteristics. No more than 3% of data
weremissing for any particular variable, so
for simplicity only the first imputed data set
was used in modeling.
Models used only the first SHE per
patient and assumed that there were no
time-dependent covariates associated
with both SHEs and clinical outcomes.
Events per 100 patient-years of follow-up
are presented separately for the time
from first SHE to clinical outcome and for
time to clinical outcome or censor without
an SHE. Results are displayed as forest
plots. Similar models were fitted to inves-
tigate theassociationbetweennonfatal CV
outcomes and subsequent SHEs. All models
included randomized treatment and were
stratified by region. Data were analyzed
using SAS software version 9.4 (SAS Insti-
tute, Inc., Cary, NC) with P values ,0.05
considered statistically significant.
RESULTS
The TECOS intention-to-treat population
consisted of 14,671 participants with a
median follow-up of 3.0 years (interquar-
tile range 2.3, 3.8; maximum 5.7). Of par-
ticipantsallocated to sitagliptin andplacebo,
95.1% and 94.1%, respectively, completed
the study, with premature discontinua-
tion of study medication in 26.1% and
27.5%, respectively. Vital status was avail-
able for 97.5%of participants at study end.
SHEswere uncommon,with 303 (2.1%)
TECOS participants reporting one ormore
(10). Table 1 lists the baseline character-
isticsof thosewithandwithout SHEsduring
the trial. Participants with SHEs, compared
with thosewithout, tended to be olderwith
longer mean duration of diabetes, lower
mean body weight, and lower mean eGFR.
They were also more frequently women,
Table 1—Baseline characteristics for participants with and without SHEs (intention-
to-treat population)
With SHEs (N = 303) Without SHEs (N=14,368)
Age at randomization, years* 67 (62, 73) 65 (60, 71)
,65 109 (36.6) 6,507 (46.3)
$65 189 (63.4) 7,546 (53.7)
,70 176 (59.1) 9,666 (68.8)
$70 122 (40.9) 4,387 (31.2)
Sex
Male 193 (63.7) 10,181 (70.9)
Female 110 (36.3) 4,187 (29.1)
Race
White 176 (58.1) 9,781 (68.1)
Black 21 (6.9) 426 (3.0)
Asian 74 (24.4) 3,191 (22.2)
Other 32 (10.6) 970 (6.8)
Duration of type 2 diabetes, years† 14 (8, 22) 10 (5, 16)
Duration of type 2 diabetes$15 years 146 (48.2) 4,144 (28.9)
Diabetes therapy at baseline (alone or in
combination)
Sulfonylurea 140 (46.2) 6,505 (45.3)
Metformin 226 (74.6) 11,740 (81.7)
Thiazolidinedione (includes pioglitazone) 8 (2.6) 388 (2.7)
Insulin 129 (42.6) 3,279 (22.8)
Not on sulfonylurea or insulin 40 (13.2) 4,679 (32.6)
Preexisting vascular disease 302 (99.7) 14,288 (99.4)
Previous MI 118 (38.9) 6,137 (42.7)
Previous congestive heart failure 54 (17.8) 2,589 (18.0)
Current smoking 25 (8.3) 1,653 (11.5)
Qualifying HbA1c
mmol/mol 56 (52, 61) 55 (51, 60)
% 7.3 (6.9, 7.7) 7.2 (6.8, 7.6)
Qualifying HbA1c categories, %
,7 87 (28.7) 4,895 (34.1)
$7 to,7.5 97 (32.0) 4,410 (30.7)
$7.5 119 (39.3) 5,058 (35.2)
eGFR, mL/min/1.73 m2 64.0 (52.0, 82.3) 73.0 (60.0, 88.0)
eGFR categories, mL/min/1.73 m2‡
$60 189 (63.0) 11,015 (77.4)
,60 111 (37.0) 3,213 (22.6)
UACR categories, g/mol§
Normoalbuminuria,,30 73 (56.2) 3,605 (71.8)
Microalbuminuria,$30 to,300 46 (35.4) 1,173 (23.4)
Macroalbuminuria,$300 11 (8.5) 240 (4.8)
Blood pressure, mmHg
Systolic 134 (125, 149) 134 (124, 145)
Diastolic 75 (67, 82) 79 (70, 84)
BMI categories, kg/m2
,25 55 (18.3) 2,348 (16.5)
$25 to,30 121 (40.2) 5,211 (36.6)
$30 to,35 76 (25.2) 4,174 (29.3)
$35 49 (16.3) 2,500 (17.6)
Weight, kg 79.8 (69.0, 92.5) 83.0 (71.7, 97.0)
Medications taken at time of randomization
Statins 257 (84.8) 11,462 (79.8)
ACE inhibitors or ARBs 241 (79.5) 11,314 (78.7)
Diuretics 144 (47.5) 5,876 (40.9)
Calcium channel blockers 109 (36.0) 4,852 (33.8)
b-Blockers 194 (64.0) 9,128 (63.5)
Aspirin 245 (80.9) 11,273 (78.5)
Other platelet antagonists 77 (25.4) 3,110 (21.6)
Data are n (%) or median (Q1, Q3). UACR, urine albumin-to-creatinine ratio. *Age is missing among
patients enrolled in Lithuania because the entire birth date including year was not available.
†Duration = (year of randomization – year of diagnosis) + 1. ‡MDRD formula was used to calculate
the eGFR. Site-reported values are presented in the table. §Available for 130 patients with SHEs and
5,018 without SHEs.
nonwhite, and on insulin treatment and
more often had microalbuminuria or mac-
roalbuminuria. Rates of reported previous
MI and congestive heart failurewere similar
between the two groups, but participants
with SHEs were more often being treated
with diuretics, statins, and antithrombotic
agents.
The incidence of SHEs did not differ
between those assigned to the sitagliptin
(N = 160 [2.2%], 0.78 per 100 patient-
years) or placebo (N = 143 [1.9%], 0.70
per 100 patient-years) groups (HR 1.12
[95% CI 0.89, 1.40], P = 0.33), as shown
in Fig. 1. SHE rates were higher in the first
year than in the second and third years in
both groups (Fig. 1). Only one patient per
treatment arm discontinued study drug
due to two SHEs occurring between study
visits. Of the 303 participants with SHEs,
68 (22.4%) also had a 4-point MACE or
hHF event. They tended to be older with
higher mean body weight and lower
mean eGFR and were more often on in-
sulin therapy or more likely to have had
an MI or heart failure with more preva-
lent use of b-blockers, diuretics, and sta-
tins at baseline (Supplementary Table 2).
Of these 68 participants with SHEs and a
4-point MACE or hHF event, 34 had an SHE
with a subsequent MACE or hHF event,
38 had a 4-point MACE or hHF event
with a subsequent SHE, and 7 had an SHE
both before and after a 4-point MACE or
hHF event. In three cases, participants
had a single SHE and a 4-point MACE or
hHF event on the sameday, sowhich event
developed first could not be determined.
Association Between SHEs and
Subsequent CV or hHF Events or Death
In unadjusted analyses (Fig. 2A), SHEs
were associated with a subsequent
4-point MACE (HR 1.57 [95% CI 1.07,
2.31], P = 0.020), all-cause death (1.91
[1.27, 2.88], P = 0.002), and CV death
(1.81 [1.08, 3.02], P = 0.024). There was
also a significant association with a sub-
sequent 3-point MACE.
After adjustment for selected clinical
(demographic) factors (Fig. 2B), all of
these associations remained statistically
significant: 4-point MACE (HR 1.55 [95%
CI 1.06, 2.28], P = 0.025), all-cause death
(1.83 [1.22, 2.75], P = 0.004), and CV
death (1.72 [1.02, 2.87], P = 0.040). How-
ever, these associations all became non-
significant after further adjustment for
baseline variables that were significantly
associated with CV events (Fig. 2C). No
associations were seen between SHEs and
a subsequent fatal/nonfatalMI, hospitaliza-
tion for unstable angina, fatal/nonfatal
stroke, or hHF in any of the models.
Association Between Nonfatal CV or
hHF Events and Subsequent SHEs
In unadjusted analyses (Fig. 3A), SHEs
were associated with a previous nonfatal
MI, hospitalization for unstable angina, or
nonfatal stroke (HR 2.46 [95% CI 1.63,
3.70], P , 0.001), nonfatal MI (2.99
[1.82, 4.90], P , 0.001), nonfatal stroke
(2.75 [1.35, 5.57], P = 0.005), and hHF
(3.90 [2.27, 6.70], P , 0.001).
After adjustment for clinical factors (Fig.
3B), all of these associations remained
statistically significant: nonfatal CV event
or hospitalization for unstable angina
(2.48 [1.65, 3.75], P , 0.001), nonfatal
MI (3.02 [1.83, 4.96], P, 0.001), nonfatal
stroke (2.77 [1.36, 5.63], P = 0.005), and
hHF (3.68 [2.13, 6.36], P , 0.001).
These associations remained statisti-
cally significant after further adjustment
for the wider range of baseline variables
(Fig. 3C): nonfatal CV event or hospitaliza-
tion for unstable angina (1.96 [1.29, 2.98],
P = 0.001), nonfatal MI (2.31 [1.39, 3.82],
P = 0.001), nonfatal stroke (2.07 [1.01,
4.23], P = 0.046), and hHF (2.26 [1.28,
3.99], P = 0.005).
CONCLUSIONS
Our post hoc analysis of TECOS data
found a relatively low rate of SHEs among
participants with type 2 diabetes and es-
tablished CV disease, with no increased
SHE risk in those randomized to sitagliptin.
A novel finding was a robust association
between SHEs and previous major CV
events, with a near doubling in the risk of
an SHE following a nonfatal CV or hHF
event, even after full statistical adjustment.
The bidirectional relationship between
SHEs and CV outcomes suggests that there
may be a common “frail” type 2 diabetes
phenotype of patients who are suscepti-
ble to both of these events. Thus SHEs,
rather than being causative of MACE,
hHF, or all-cause death events,may simply
be indicative of patients with a frail type 2
diabetesphenotypewhoare at high risk of
both outcomes likely due to amultitudeof
coexisting risk factors.
Post hoc analyses of other large-scale
CV outcome trials have also reported as-
sociations between SHEs and subsequent
CV events, primarily related to fatal out-
comes (1–3,5). The Examination of Car-
diovascular Outcomes with Alogliptin
versus Standard of Care (EXAMINE) study
observed an association of SHEs with
MACE that became nonsignificant when
considering the time sequence of SHE and
MACE (Supplementary Table 1) (11). The
Saxagliptin Assessment of Vascular Out-
comes Recorded in Patients with Diabe-
tes Mellitus–Thrombolysis in Myocardial
Infarction 53 (SAVOR-TIMI 53) trial found
Figure 1—Kaplan-Meier plot of time to first SHE for sitagliptin- and placebo-assigned participants
(intention-to-treat population).
an association of SHEs with CV death but
not with MI (12). These findings to some
extent may be consistent with the results
in TECOS, but the time-dependent aspects
remain presently unclear.
Considerable efforts have been made to
provide biologically plausible mechanisms
whereby SHEs might indicate higher risks
of CV events andmortality. Severe hypogly-
cemia is known to induce a wide range of
potentiallyadverseeffects in thevasculature
and the heart, such as neurosympathetic
overdrive with the risk of arrhythmias, acti-
vation of proinflammatory and prothrom-
boticpathways, andendothelial dysfunction
(13–18). In this context, a link of SHEswith
fatal CV and all-cause death outcomes may
seem reasonable; however CV outcome tri-
als arenotdesigned toelucidatepathophys-
iologic mechanisms, and the link between
SHEs and MACE or hHF outcomes may be
quite complex. Our results suggest that the
association seems tobebidirectional,witha
common frail phenotype explaining the
susceptibility to both SHEs and worse clini-
cal outcomes.
In TECOS, baseline characteristics for
participants who suffered within-study
SHEs suggested that they did indeed dif-
fer from those without SHEs, being older,
more likely to be insulin treated, women,
and nonwhite, and with a longer diabetes
duration, lower eGFR, and lower weight.
These observations are in accord with
published information fromother CV out-
come trials. Of note, previous history of
Figure 2—Associationbetween SHEs and subsequent riskof CVeventsor death.A: Unadjusted.B: Adjusted for clinical factors (randomized treatment, age,
sex, race, weight, and smoking). C: Full adjustment. HF, heart failure; UA, unstable angina; pt-years, patient-years.
CVdisease or heart failurewas not related
to SHEs, nor was the use of b-blockers,
ACE inhibitors, or angiotensin II receptor
blockers (ARBs) at baselinedfactors that
could have influenced the occurrence of
SHEs in light of the present findings or
earlier publications (13–20). Given that
established CV disease was an inclusion
criterion for enrollment in TECOS, it is not
unreasonable to seenodifferences.Among
the 303 patients with SHEs in TECOS, how-
ever, those with CV events and hHF versus
those without did show higher baseline
rates of previousMI andHF,more frequent
use of diuretics, b-blockers, statins, ACE
inhibitors or ARBs, and insulin together
with a lower eGFR (Supplementary Table
2), again alluding to a common particu-
larly frail type 2 diabetes phenotype of
patients susceptible to both SHEs and
CV events or hHF events. Epidemiologic
observations from the Hong Kong Diabe-
tes Registry seem to support this novel
concept (21,22).
Strengths of our study include its size
and length of follow-up, adjudication of all
relevant events, and that SHEs were cap-
tured proactively by a structured process.
Weaknesses include its post hoc nature,
with any findings from this subgroup iden-
tified in postrandomization data being no
more thanhypothesis generating, aswell as
the low SHE rates and the lack of bio-
markers that could provide greater mecha-
nistic insights. There could also be possible
confounding from changes in therapy
Figure 3—Association between nonfatal CV events or hospitalization for unstable angina (hUA) or hospitalization for heart failure (HF) and subsequent
SHEs. A: Unadjusted. B: Adjusted for clinical factors (randomized treatment, age, sex, race, weight, and smoking). C: Full adjustment.
following SHEs, MACE, or hHF events, e.g.,
switch to insulin from oral agents, that
could impact future risk of SHEs and/or
CV events.
In conclusion, while it remains impor-
tant to seek tominimize the risk of SHEs in
people with type 2 diabetes, the focus on
attaining good glycemic control to mini-
mize the risk of diabetes complications
should not be unduly compromised. A pre-
cisionmedicine approach is required to de-
lineate those with a frail phenotype who
need special consideration from those
likely to benefit from more aggressive gly-
cemic targets.
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